Current Treatment Options for Malignant Peripheral Nerve Sheath Tumors

Current Treatment Options in Oncology

Volumn 16, Issue 3, 2015, Pages

  Bradford, Diana ^a   Kim, AeRang ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Atypical neurofibroma; Malignant peripheral nerve sheath tumor; MEK inhibitor; mTOR inhibitor; Neurofibromatosis type 1; Plexiform neurofibroma; Proteotoxic stress; Soft tissue sarcoma; Targeted therapy

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; IFOSFAMIDE; IMATINIB; RAPAMYCIN; RAS PROTEIN; SORAFENIB; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; DRUG EFFICACY; ENDOPLASMIC RETICULUM STRESS; GENETIC PREDISPOSITION; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SURGICAL TECHNIQUE; TREATMENT RESPONSE; ADJUVANT THERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTIMODALITY CANCER THERAPY; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS TYPE 1; PATHOLOGY; PROGNOSIS; SARCOMA; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SARCOMA; TREATMENT OUTCOME;

EID: 84924955739     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-015-0328-6     Document Type: Review

References (44)

1. Widemann BC. Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep. 2009;11(4):322–8.
2. Ducatman BS et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57(10):2006–21.
3. Evans DG et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39(5):311–4.
4. Meany H, Widemann BC, Ratner N. Malignant peripheral nerve sheath tumors: prognostic and diagnostic markers and therapeutic targets. In: Neurofibromatosis Type 1. Berlin: Springer; 2012. p. 445–67. An updated overall review of MPNST biology and potential targets.
5. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001;104(4):593–604.
6. Carli M et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol. 2005;23(33):8422–30.
7. Stucky CC et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19(3):878–85. Recent, large, single-institution retrospective review to evaluate prognostic variables in this rare tumor type.
8. Beert E et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosom Cancer. 2011;50(12):1021–32.
9. Kourea HP et al. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol. 1999;155(6):1855–60.
10. Nielsen GP et al. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol. 1999;155(6):1879–84.
11. Wong WW et al. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998;42(2):351–60.
12. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20(3):791–6.
13. Kolberg M. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol. 2013;15(2):135–47. This analysis examines survival in MPNST and demonstrates improved survival NF1-associated MPNST compared to sporadic tumors, contrary to historical data.
14. Johannessen CM et al. TORC1 is essential for NF1-associated malignancies. Curr Biol. 2008;18(1):56–62.
15. Endo M et al. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res. 2013;19(2):450–61. This study examined activation profiles of the AKT/mTOR and MAPK pathways in tumor specimens and correlated these results with prognosis. The study also assessed the in vitro activity of everolimus, which demonstrated antitumor activity in MPNST cell lines, providing insight into potential therapeutic pathways.
16. Bottillo I et al. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J Pathol. 2009;217(5):693–701.
17. Pasmant E et al. Identification of genes potentially involved in the increased risk of malignancy in NF1-microdeleted patients. Mol Med. 2011;17(1–2):79–87.
18. Watson MA et al. Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol. 2004;14(3):297–303.
19. Brekke HR et al. Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. J Clin Oncol. 2010;28(9):1573–82.
20. Ferner R et al. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 2000;68(3):353–7.
21. Benz MR et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer. 2010;116(2):451–8.
22. Ferner R et al. [18F] 2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008;19(2):390–4.
23. Bensaid BGF, Mognetti T, Galoisy-Guibal L, Pinson S, Drouet A, Combemale P. Utility of 18 FDG positron emission tomography in detection of sarcomatous transformation in neurofibromatosis type 1. Ann Dermatol Venereol. 2007;134(10 Pt 1):735–41.
24. Bredella MA et al. Value of PET in the assessment of patients with neurofibromatosis Type 1. Am J Roentgenol. 2007;189(4):928–35.
25. Scaife CL, Pisters PW. Combined-modality treatment of localized soft tissue sarcomas of the extremities. Surg Oncol Clin N Am. 2003;12(2):355–68.
26. Pisters PW et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679–89.
27. Gupta G, Mammis A, Maniker A. Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am. 2008;19(4):533–43. v.
28. Yang JC et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16(1):197–203.
29. Kahn J et al. Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol. 2014;4:324.
30. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62(5):1573–7.
31. Widemann B, et al. SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs). J Clin Oncol. 2013; 31 (suppl; abstr 10522).
32. Raney B et al. Treatment of children with neurogenic sarcoma experience at the children's hospital of Philadelphia, 1958–1984. Cancer. 1987;59(1):1–5.
33. Li H et al. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res. 2002;62(15):4507–13.
34. Maki RG et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27(19):3133–40.
35. Chugh R et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009;27(19):3148–53.
36. Albritton K, et al. Phase II trial of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumor (MPNST). J Clin Oncol. 2006; 24 (suppl; abstr 9518).
37. Schuetze S, et al. Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma. J Clin Oncol. 2010; 28(15s (suppl; abstr 10009)).
38. Johansson G et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2008;7(5):1237–45.
39. Vogel KS et al. Mouse tumor model for neurofibromatosis Type 1. Science (New York, NY). 1999;286(5447):2176–9.
40. Cichowski K et al. Mouse models of tumor development in neurofibromatosis type 1. Science. 1999;286(5447):2172–6.
41. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136(5):823–37.
42. De Raedt T et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell. 2011;20(3):400–13. This study demonstrated that promotion of proteotoxic stress on the endoplasmic reticulum via Hsp90 inhibition in combination with mTOR inhibition resulted in irreparable damage to mitochondria and ER, which correlated with dramatic tumor shrinkage in a transgenic MPNST mouse model. This promising finding led to the rapid development of SARC023, a Phase I/II study of gantespib and sirolimus in MPNST.
43. Kim A, et al. SARC023: Phase I/II trial of ganetespib in combination with sirolimus for refractory sarcomas and malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol. 2014; 32(5s (suppl; abstr TPS10603)).
44. 18FDG-PET was identified as a potential real-time indicator for target inhibition by these agents, and thus identifying a potential imaging biomarker for evaluation in clinical trials.